Pricing Log in Create free account
Friday 6 November 2026 Export BTAIQ’s income statement to Excel — free account

BioXcel Therapeutics, Inc.

BTAIQ Healthcare Drug Manufacturers Specialty & Generic

BioXcel Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $642,000.00, down 71.7% from fiscal 2024.

Revenue
+51.7%
EPS
+80.0%
Free cash flow
+51.5%
Total debt
−3.90%

Quarter to June 2026, against a year earlier

0.01 0.00 0.00%
Market cap
$2.3M
P/E
0.0×
Fwd P/E
−0.4×
Dividend yield
—
F-score
2/9
Altman Z
−26.30
Beneish M
−0.61
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 0.04
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — 4 — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 2.31
Revenue ttm 0.74
Net income ttm (70.86)
Free cash flow ttm (50.90)
Net debt Q 90.65
Valuation
P/E 0.00
Forward P/E (0.42) (negative: loss-making)
Price / sales 0.41
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.00
Financial health
Current ratio Q 0.21 (below 1: weak)
Debt / equity Q (0.90) (negative: negative equity)
Interest coverage Q (2.39)
Growth
Revenue growth Q +51.67% (above 0%: growing)
Operating income growth Q +35.70% (above 0%: growing)
EPS, this year +52.88% (at or above 15%: strong)
EPS, next year A +20.74% (at or above 15%: strong)
Revenue, next year A +19.92% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +48.34% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 228×, against a ten-year median of 99.7×; over the ten years it ranged from 29.9× in 2024 to 285× in 2026.
P/S against its own 10 years 0.95%
10-year low 10-year high
EV/Sales against its own 10 years 87.89%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 65 30 29 14
Receivables 0 0 0 0
Inventory 2 1 1 0
Other 2 1 11 11
72 37 45 29
2023 2024 2025 Q'26
Payables 14 16 15 19
ST’ Debt — — 25 104
Other 0 0 10 10
27 22 54 137

Compound Annual Growth %

10y 5y 3y
Sales — — 19.63%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% 0.00%

EPS $

Mar Jun Sep Dec Year
’26 (0.54) (0.49) — — —
’25 (1.50) (2.45) (2.18) (0.58) (5.73)
’24 (13.92) (3.36) (5.12) (3.57) (23.51)
’23 (29.44) (29.28) (27.52) (12.16) (98.40)
’22 (17.92) (21.60) (23.84) (31.20) (94.72)
’21 (17.28) (17.76) (15.36) (14.88) (64.80)
’20 (12.64) (16.96) (17.12) (13.92) (60.64)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 0 0 0 0 1
’24 1 1 0 0 2
’23 0 0 0 0 1
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (12) (6) — — —
’25 (12) (13) (19) (14) (58)
’24 (18) (23) (16) (15) (72)
’23 (52) (38) (38) (27) (155)
’22 (32) (33) (31) (39) (135)
’21 (20) (22) (20) (20) (82)
’20 (12) (15) (19) (20) (66)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (12) (6) — — —
’25 (12) (13) (19) (14) (58)
’24 (18) (23) (16) (15) (72)
’23 (52) (38) (38) (27) (155)
’22 (33) (33) (31) (39) (135)
’21 (20) (22) (20) (20) (83)
’20 (12) (15) (19) (21) (67)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

4
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — — — — 0 1 2 1 1 +19.6% 1 21 63 +362.0%
Gross margin, % — 0.00 0.00 0.00 0.00 0.00 94.67 8.70 5.43 74.45 53.10 +74.5 pt
EBT (2) (5) (19) (33) (82) (107) (166) (179) (60) (70) (71) +47.5%
EBT margin, % 0.00 0.00 0.00 0.00 0.00 0.00 (44,201.87) (12,974.86) (2,630.14) (10,887.38) (9,549.87) (10,887.4) pt
Net income (2) (5) (19) (33) (82) (107) (166) (179) (60) (70) (71) +47.5%
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.00 0.00 0.00 0.21 0.76 0.89 0.05 0.02 n/m
Earnings (3.58) (7.50) (21.12) (32.32) (60.64) (64.80) (94.72) (98.40) (23.51) (5.73) (3.79) +5.4%
Cash flow (2.18) (3.63) (14.83) (26.62) (48.96) (49.84) (77.30) (85.12) (28.41) (4.72) (1.68) +8.9%
Capex (0.01) 0.00 (0.37) (0.85) (0.23) (0.27) (0.08) (0.01) 0.00 0.00 0.00 n/m
Free cash flow (2.19) (3.63) (15.21) (27.47) (49.19) (50.11) (77.38) (85.13) (28.41) (4.72) (1.68) +8.9%
Book value (0.55) (1.62) 42.70 26.42 152.52 134.48 43.85 (31.03) (36.73) (7.82) (3.81) +34.4%
Shares, m 1 1 1 1 1 2 2 2 3 12 20 +40.0%
Valuation, ×
Valuation, × P/E — — — — — — 0.00 0.00 0.00 0.00 0.00 0.0
P/S — — — — — — 0.00 61.86 6.69 30.42 0.41 24.7
P/B — — — — — — 7.83 0.00 0.00 0.00 0.00 2.0
EV/Sales — — — — — — 0.00 87.74 38.90 156.34 227.51 70.7
EV/FCF — — — — — — (3.70) (0.78) (1.22) (1.74) (3.31) (1.9)
Cash, $m
Cash, $m Operating cash flow (1) (2) (14) (27) (66) (82) (135) (155) (72) (58) (51) +52.5%
Capex 0 — 0 (1) 0 0 0 0 — — 0 +25.8%
Free cash flow (1) (2) (14) (28) (67) (83) (135) (155) (72) (58) (51) +52.4%
Balance, $m
Balance, $m Working capital 0 (1) 39 26 205 220 170 45 15 (9) (108) +44.9%
Net debt — (1) (43) (31) (211) (232) (100) 35 73 81 91 n/m
Shareholders’ equity 0 (1) 39 27 207 222 77 (57) (93) (95) (115) +88.1%
Returns, %
Returns, % ROA (311.31) (666.52) (85.83) (82.48) (64.11) (46.55) (74.45) (128.10) (106.39) (167.91) (259.62) +143.4 pt
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0 pt
ROE 324.66 695.10 (101.67) (100.23) (70.35) (49.93) (111.08) (1,766.94) 79.67 74.14 63.52 (250.5) pt
People
People Employees — 6 18 24 50 89 183 74 37 29 — +21.8%
Revenue/emp, $m — 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.06 0.02 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

BioXcel Therapeutics, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
YCBD cbdMD, Inc. $4.4M — (loss-making) — (loss-making) +20.55% (above 0%: growing) n/m +34.80% (above 0%: growing) 54.69% (20.36%) Compare
APUS Apimeds Pharmaceuticals US, Inc. $4.1M — (loss-making) — — n/m −67.94% (below 0%: shrinking) — 0.00% Compare
RDHL Redhill Biopharma Ltd. $3.8M — (loss-making) — (loss-making) −90.32% (below 0%: shrinking) n/m −107.31% (below 0%: shrinking) (7.52%) 0.00% Compare
BTAIQ BioXcel Therapeutics, Inc. $2.3M — (loss-making) — (loss-making) +51.67% (above 0%: growing) n/m +51.51% (above 0%: growing) 87.91% (5,600.55%)
PRFX PainReform Ltd. $2.3M — (loss-making) — (loss-making) — n/m +52.56% (above 0%: growing) 0.00% 0.00% Compare
AKAN Akanda Corp. $2.2M — — — — −472.01% (below 0%: shrinking) (197.87%) 0.00% Compare
SBFM Sunshine Biopharma, Inc. $2.1M — (loss-making) — (loss-making) −1.56% (below 0%: shrinking) n/m +49.38% (above 0%: growing) 26.20% (17.41%) Compare
SXTC China SXT Pharmaceuticals, Inc. $2.0M — (loss-making) — (loss-making) −16.76% (below 0%: shrinking) +92.67% (above 0%: growing) −107.59% (below 0%: shrinking) 44.09% 0.00% Compare
IMCC IM Cannabis Corp. $980.0K — (loss-making) — (loss-making) −40.28% (below 0%: shrinking) n/m −266.81% (below 0%: shrinking) 19.83% (27.54%) Compare
Median of peers $2.3M — — −16.76% — −87.62% 19.83% 0.00%

All 84 Drug Manufacturers Specialty & Generic stocks →

Pay and ownership Proxy statement filed 12 November 2025

Chief executive’s pay

Year Total pay Actually paid $100 invested
2024 1.12m 385.62k 1.84
2023 4.73m (2.86m) 14.51
2022 4.56m 5.37m 105.66

Ownership

Directors and executive officers, together 3.70%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

BioXcel Therapeutics, Inc. (BTAIQ) Latest News

12 Sep

Impact 4 ·

4 Sep

Impact 4 ·

31 Aug

Impact 4 ·
Impact 4 · · pharmaceutical-technology.com
Impact 4 · · hospitalmanagement.net

28 Aug

Impact 4 ·
Impact 4 ·

13 Aug

Impact 3 ·

2 Jun

Impact 3 · · Zacks

28 May

Impact 4 · · GlobeNewswire

15 May

Impact 4 · · GlobeNewswire
Impact 3 · · Zacks

4 May

Impact 3 · · Zacks

17 Apr

Impact 4 · · Insider Monkey
Impact 4 · · GlobeNewswire

13 Apr

Impact 4 · · Simply Wall St.

8 Apr

Impact 4 ·

1 Apr

Impact 4 · · GlobeNewswire

29 Mar

Impact 4 · · Simply Wall St.

27 Mar

Impact 4 · · GlobeNewswire

12 Mar

Impact 4 · · Simply Wall St.

11 Mar

Impact 4 · · GlobeNewswire

10 Mar

Impact 4 · · GlobeNewswire

5 Mar

Impact 4 · · GlobeNewswire

12 Feb

Impact 4 · · GlobeNewswire

20 Jan

Impact 4 · · GlobeNewswire

17 Jan

Impact 4 · · Barchart

12 Jan

Impact 4 ·

7 Jan

Impact 4 · · GlobeNewswire

4 Dec

Impact 4 · · Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.
stockrow.com/BTAIQ · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com